Literature DB >> 30617967

The paramount role of cytokines and chemokines in papillary thyroid cancer: a review and experimental results.

Poupak Fallahi1, Silvia Martina Ferrari1, Simona Piaggi2, Michaela Luconi3, Giulia Cantini3, Stefania Gelmini4, Giusy Elia1, Ilaria Ruffilli1, Alessandro Antonelli5.   

Abstract

Our study demonstrates that (C-X-C motif) ligand 9 and 11 (CXCL9, CXCL11) chemokines were absent basally in non-neoplastic thyroid (TFC) and papillary thyroid carcinoma (PTC) cells. Interferon (IFN)γ induced the chemokine secretion in TFC and PTC, while tumor necrosis factor (TNF)α induced it only in PTC. IFNγ+TNFα induced a synergistic chemokines release in PTC, and at a lower level in TFC. Peroxisome proliferator-activated receptor (PPAR)γ agonists suppressed dose-dependently IFNγ+TNFα-induced chemokine release in TFC, while stimulated it in PTC. PPARγ knocking down, by RNA interference technique in PTC cells, abolished the effect of PPARγ agonists on chemokines release. In PTC cells, PPARγ agonists reduced proliferation, and CXCL9 or CXCL11 (100 and 500 pg/mL) reduced proliferation and migration (P < 0.01, for all). In conclusion, in PTC cells: (a) IFNγ+TNFα induced a marked release of CXCL9 and CXCL11; (b) PPARγ agonists stimulated CXCL9 and CXCL11 secretion, while inhibited proliferation; (c) CXCL9 and CXCL11 inhibited proliferation and migration. The use of CXCL9 or CXCL11 as antineoplastic agents in PTC remains to be explored. HIGHLIGHTS: • IFNγ and IFNγ+TNFα induce dose-dependently CXCL9 (and less CXCL11) in PTC cells. • Rosi and Pio dose-dependently inhibit the PTC cells proliferation. • Rosi and Pio (at variance of normal TFC) stimulate CXCL9 or CXCL11 secretion. • CXCL9 or CXCL11 induce a significant antiproliferative effect in PTC cells. • Chemokines induced by IFNγ (CXCL9 or CXCL11) inhibit migration in PTC cells.

Entities:  

Keywords:  CXCL10; CXCL11; CXCL9; PPARγ; Papillary thyroid cancer

Mesh:

Substances:

Year:  2018        PMID: 30617967     DOI: 10.1007/s12026-018-9056-x

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  57 in total

1.  A functional IFN-gamma-inducible protein-10/CXCL10-specific receptor expressed by epithelial and endothelial cells that is neither CXCR3 nor glycosaminoglycan.

Authors:  K Soejima; B J Rollins
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

2.  The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis.

Authors:  Paul J Hensbergen; Pepijn G J T B Wijnands; Marco W J Schreurs; Rik J Scheper; Rein Willemze; Cornelis P Tensen
Journal:  J Immunother       Date:  2005 Jul-Aug       Impact factor: 4.456

3.  Expression and function of the chemokine receptor CCR7 in thyroid carcinomas.

Authors:  Margarida Sancho; Joaquim Miguel Vieira; Cristina Casalou; Marta Mesquita; Teresa Pereira; Branca Maria Cavaco; Sérgio Dias; Valeriano Leite
Journal:  J Endocrinol       Date:  2006-10       Impact factor: 4.286

4.  CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes.

Authors:  Alessandro Antonelli; Silvia Martina Ferrari; Silvia Frascerra; Cinzia Pupilli; Caterina Mancusi; Maria Rita Metelli; Claudio Orlando; Ele Ferrannini; Poupak Fallahi
Journal:  J Clin Endocrinol Metab       Date:  2010-09-01       Impact factor: 5.958

5.  Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone.

Authors:  Alessandro Antonelli; Silvia Martina Ferrari; Poupak Fallahi; Simona Piaggi; Aldo Paolicchi; Stefano Sellari Franceschini; Mario Salvi; Ele Ferrannini
Journal:  Metabolism       Date:  2010-03-06       Impact factor: 8.694

6.  Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines.

Authors:  Jin-Woo Park; Rasa Zarnegar; Hajime Kanauchi; Mariwil G Wong; William C Hyun; David G Ginzinger; Margaret Lobo; Philip Cotter; Quan-Yang Duh; Orlo H Clark
Journal:  Thyroid       Date:  2005-03       Impact factor: 6.568

7.  High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis.

Authors:  Alessandro Antonelli; Clodoveo Ferri; Poupak Fallahi; Silvia Martina Ferrari; Silvia Frascerra; Marco Sebastiani; Ferdinando Franzoni; Fabio Galetta; Ele Ferrannini
Journal:  Cytokine       Date:  2008-02-20       Impact factor: 3.861

8.  Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells.

Authors:  Alessandro Antonelli; Silvia Martina Ferrari; Poupak Fallahi; Piero Berti; Gabriele Materazzi; Michele Minuto; Riccardo Giannini; Ivo Marchetti; Lucio Barani; Fulvio Basolo; Ele Ferrannini; Paolo Miccoli
Journal:  Clin Endocrinol (Oxf)       Date:  2008-09-10       Impact factor: 3.478

9.  Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes.

Authors:  Kenji Kawada; Masahiro Sonoshita; Hiromi Sakashita; Arimichi Takabayashi; Yoshio Yamaoka; Toshiaki Manabe; Kayo Inaba; Nagahiro Minato; Masanobu Oshima; Makoto Mark Taketo
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

Review 10.  Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer.

Authors:  Silvia Martina Ferrari; Gabriele Materazzi; Enke Baldini; Salvatore Ulisse; Paolo Miccoli; Alessandro Antonelli; Poupak Fallahi
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

View more
  6 in total

1.  Editorial: autoimmunity-the ever endless world.

Authors:  Elias Toubi
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

Review 2.  Fish and the Thyroid: A Janus Bifrons Relationship Caused by Pollutants and the Omega-3 Polyunsaturated Fatty Acids.

Authors:  Salvatore Benvenga; Fausto Famà; Laura Giovanna Perdichizzi; Alessandro Antonelli; Gabriela Brenta; Francesco Vermiglio; Mariacarla Moleti
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-27       Impact factor: 6.055

3.  High Expression of Interleukin-12A and Its Association with the Clinicopathology and Prognosis of Differentiated Thyroid Cancer.

Authors:  Guo-Qiang Zhang; Chen-Tian Shen; Hong-Jun Song; Zhong-Ling Qiu; Quan-Yong Luo
Journal:  Eur Thyroid J       Date:  2020-04-17

4.  CXCL10 is a potential biomarker and associated with immune infiltration in human papillary thyroid cancer.

Authors:  Xiao-Jing Qin; Xu Lin; Gang Xue; Hui-Li Fan; Hao-Yu Wang; Jing-Fang Wu; Da Pei
Journal:  Biosci Rep       Date:  2021-01-29       Impact factor: 3.840

Review 5.  Immune and Inflammatory Cells in Thyroid Cancer Microenvironment.

Authors:  Silvia Martina Ferrari; Poupak Fallahi; Maria Rosaria Galdiero; Ilaria Ruffilli; Giusy Elia; Francesca Ragusa; Sabrina Rosaria Paparo; Armando Patrizio; Valeria Mazzi; Gilda Varricchi; Gianni Marone; Alessandro Antonelli
Journal:  Int J Mol Sci       Date:  2019-09-07       Impact factor: 5.923

6.  Identification of Key Genes in Thyroid Cancer Microenvironment.

Authors:  Kankan Zhao; Hao Yang; Houlong Kang; Aiguo Wu
Journal:  Med Sci Monit       Date:  2019-12-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.